Accredited e-learning: The Role of PARP inhibition in Clinical Practice

 

DNA Damage Response (DDR) and PARP inhibitors are promising but complex therapeutic strategies.

Understand why, where and how PARP inhibitors work in clinical practice, and look into the future of targeting DDR with this interactive free to access e-learning course. Designed to support you in selecting the appropriate treatment strategy with PARP inhibitors in the appropriate patient population and to provide the best possible patient care.

This course is endorsed by the Innovative Breast Cancer Research Group (SOLTI), the Gynecological Cancer Group Singapore (GCGS) and the Gynecologic Oncology Trial and Investigation Consortium (GOTIC).

Downloadable slides accompany this e-learning for your own use.

 

Prof. Jonathan A. Ledermann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics. 

Dr Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche. 

Dr Robert L. Coleman has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Aravive, ArQuel, Cell Medica, Clovis, Geistlich Pharma, Genetech, GenMab, ImmunoGen, Janssen, Medscape, Merck, Mersana, MoreHealth, OncLive, OncoMed, Physicians Educational Resource, Takeda, Tesaro, TRM Oncology and United Therapeutics. 

Prof. Eric Pujade-Lauraine has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Clovis, Pfizer, Roche and Tesaro. 

Programme summary
  • clock Duration 60 MIN
  • clock Language(s) flag
Take the e-learning now
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Accreditation
EACCME
This course has been accredited by EACCME® for ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

conference-update Conference update

Episode

1

of 1

episode
Oncology 
Coming soon! Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

Experts
Prof. Nicolas Girard
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
ISLB
  • clock 1 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast
Oncology 
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Experts
Dr Carlos Barrios, Prof. Gary Tse, Oncology Brothers (Moderators)
Endorsed by
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Daiichi Sankyo 
eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026

This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.